Mai Capital Management Ultragenyx Pharmaceutical Inc. Transaction History
Mai Capital Management
- $13.2 Billion
- Q4 2024
A detailed history of Mai Capital Management transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Mai Capital Management holds 53 shares of RARE stock, worth $2,257. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53Holding current value
$2,257% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RARE
# of Institutions
344Shares Held
86.6MCall Options Held
675KPut Options Held
846K-
Vanguard Group Inc Valley Forge, PA10MShares$427 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$239 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA4.3MShares$183 Million0.57% of portfolio
-
State Street Corp Boston, MA2.72MShares$116 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.51MShares$107 Million0.01% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.98B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...